● Recruiting

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Condition: Ovarian Cancer · Fallopian Tube Cancers · Primary Peritoneal Cancer · Sponsor: N.N. Alexandrov National Cancer Centre

PhasePhase 2/Phase 3

Planned participants120

Who can joinFemale, 18 Years to 75 Years

Healthy volunteersNo

About this study

This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.

This description comes directly from the study's public registry record.

Talk to the study team

Hanna Trukhan · 80291985715 · annavladimir@rambler.ru

Sergey Mavrichev · smavrichev71@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

N.N. Alexandrov National Caner Centre

Minsk, Lesnoy, Belarus

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07472140